Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koller, W. C.
Right arrow Articles by Biary, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koller, W. C.
Right arrow Articles by Biary, N.
NEUROLOGY 1982;32:547
© 1982 American Academy of Neurology

Estrogen treatment of dyskinetic disorders

W. C. Koller, A. Barr and N. Biary

Department of Neurology, University of Illinois, Chicago, IL. Accepted for publication October 19, 1981.

Estrogen have been reported in animal studies to both enhance and block central dopaminergic activity and in one clinical report to improve tardive dyskinesia. In the present study estrogen (Premarin, 2.5 mg per day) administration caused varying degrees of improvement in less than one-third of 21 patients with chorea due to Huntington's disease and tradive dyskinesia and had no effect in eight patients with dystonia. Estrogens appear to have an antidopaminergic effect in humans but poses only limited efficacy in the treatment of dyskinetic disorders.

Address correspondence and reprint requests to Dr. Koller, VA Medical Center, Box 8195 (127), Chicago, IL 60680.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
L. J. Currie, M. B. Harrison, J. M. Trugman, J. P. Bennett, and G. F. Wooten
Postmenopausal Estrogen Use Affects Risk for Parkinson Disease
Arch Neurol, June 1, 2004; 61(6): 886 - 888.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K.-L. Tsang, S.-L. Ho, and S.-K. Lo
Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
Neurology, June 27, 2000; 54(12): 2292 - 2298.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. J. Blanchet, J. Fang, K. Hyland, L. A. Arnold, M. M. Mouradian, and T. N. Chase
Short-term effects of high-dose 17{beta}-estradiol in postmenopausal PD patients: A crossover study
Neurology, July 1, 1999; 53(1): 91 - 91.
[Abstract] [Full Text]

Home page
 NeurologyHome page
R. Saunders-Pullman, J. Gordon-Elliott, M. Parides, S. Fahn, H. R. Saunders, and S. Bressman
The effect of estrogen replacement on early Parkinson's disease
Neurology, April 1, 1999; 52(7): 1417 - 1417.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by AAN Enterprises, Inc.